More than four years later—and after two rejections from the agency—Mesoblast has finally gained an endorsement from the U.S.

Mesoblast Limited (AU:MSB) has released an update.Don't Miss Our Christmas Offers:Discover the latest stocks recommended by top Wall Street ...

Investment risks and competition challenge Mesoblast Limited's recent approval for Remestemcel-L in treating ...

Mesoblast announces that the FDA approved Ryoncil. Ryoncil is the only approved therapy for steroid-refractory acute graft ...

FDA approval for Mesoblast’s cell therapy used to treat children for complications that can occur during bone marrow ...

Mesoblast (NASDAQ:MESO – Get Free Report) was downgraded by investment analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a research report issued on Monday, MarketBeat ...

These shares are ending the week positively. But why? The post Why Bowen Coal, Droneshield, Mesoblast, and St Barbara shares ...

Investors are sending the Mesoblast share price tumbling on Friday. But why? The post Why the Mesoblast share price is diving ...

Mesoblast's Ryoncil is now FDA-approved for pediatric SR-aGvHD, marking a milestone in mesenchymal stromal cell therapies in ...

Mesoblast shareholders are sitting on as much as 10-fold gains for the year, after the US Food and Drug Administration ...

Mesoblast has a strong and extensive global intellectual property portfolio with protection extending through to at least 2041 in all major markets. The Company’s proprietary manufacturing ...

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast ...